PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för poziotinib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

33 hits

Bibliografisk träff 2023-12-01

Assessments of CYP‑inhibition‑based drug-drug interaction between vonoprazan and poziotinib in vitro and in vivo.

Zhou S, Zhao FL, Wang SH, Wang YR, Hong Y, Zhou Q, Geng PW, Luo QF, Cai JP, Dai DP.

Pharm Biol · research-article; journal article · DOI 10.1080/13880209.2023.2173253

Bibliografisk träff 2023-08-01

Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?

Borm FJ, Smit EF.

J Thorac Oncol · comment; editorial · DOI 10.1016/j.jtho.2023.05.002

Bibliografisk träff 2023-03-27

Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC-MS/MS.

Wang S, Xia M, Wang Y, Lu Z, Geng P, Dai D, Zhou Y, Wu Q.

Thorac Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/1759-7714.14870

Bibliografisk träff 2023-03-21

Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).

Cornelissen R, Prelaj A, Sun S, Baik C, Wollner M, Haura EB, Mamdani H, Riess JW, Cappuzzo F, Garassino MC, Heymach JV, Socinski MA, Leu SY, Bhat G, Lebel F, Le X, ZENITH20-4 Investigators.

J Thorac Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1016/j.jtho.2023.03.016

Bibliografisk träff 2023-03-14

New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.

David GM, Maria Del Pilar BC, Cristina MR.

J Oncol Pharm Pract · systematic review; journal article · DOI 10.1177/10781552231162545

Bibliografisk träff 2023-01-16

A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma.

Yang J, Yang Y, Wei Y, Wei X.

Front Med · journal article · DOI 10.1007/s11684-022-0945-y

Bibliografisk träff 2022-11-01

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials.

Wang BC, Kuang BH, Liu XX, Lin GH.

Medicine (Baltimore) · research-article; systematic review; journal article · DOI 10.1097/md.0000000000031337

Bibliografisk träff 2022-08-01

Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.

Kalra R, Chen CH, Wang J, Salam AB, Dobrolecki LE, Lewis A, Sallas C, Yates CC, Gutierrez C, Karanam B, Anurag M, Lim B, Ellis MJ, Kavuri SM.

Cancer Res · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-21-3106

Bibliografisk träff 2022-07-01

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.

Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV.

Cancer Cell · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ccell.2022.06.006

Bibliografisk träff 2022-06-08

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.

Prelaj A, Bottiglieri A, Bhat G, Washington R, Calareso G, Greco GF, Ferrara R, Brambilla M, De Toma A, Occhipinti M, Manglaviti S, Soro A, Ganzinelli M, Lo Russo G, Proto C.

Front Oncol · journal article; case reports; case-report · DOI 10.3389/fonc.2022.902967

Bibliografisk träff 2022-04-08

Poziotinib-induced cutaneous adverse reactions in the treatment of non-small cell lung cancer: A case report.

Hui H, Wang M, Guo H, Wang Y, Shi B, Shi B.

Int J Dermatol · letter; case reports · DOI 10.1111/ijd.16205

Bibliografisk träff 2021-12-01

Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro.

Ji W, Shen J, Wang B, Chen F, Meng D, Wang S, Dai D, Zhou Y, Wang C, Zhou Q.

Pharm Biol · research-article; journal article · DOI 10.1080/13880209.2021.1914114

Bibliografisk träff 2021-11-29

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.

Le X, Cornelissen R, Garassino M, Clarke JM, Tchekmedyian N, Goldman JW, Leu SY, Bhat G, Lebel F, Heymach JV, Socinski MA.

J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1200/jco.21.01323

Bibliografisk träff 2021-11-04

Diffuse scaly erythematous plaques in patient taking poziotinib.

Oldenburg R, Albukhari M, Daniels BH, Marsch AF.

JAAD Case Rep · brief-report; journal article · DOI 10.1016/j.jdcr.2021.09.042

Bibliografisk träff 2021-09-22

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.

Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV.

J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1200/jco.21.01113

Bibliografisk träff 2021-09-16

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Lee JH, Heo SG, Ahn BC, Hong MH, Cho BC, Lim SM, Kim HR.

Cancer Med · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cam4.4231

Bibliografisk träff 2021-08-04

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.

McCorkle JR, Gorski JW, Liu J, Riggs MB, McDowell AB, Lin N, Wang C, Ueland FR, Kolesar JM.

PLoS One · research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0254205

Bibliografisk träff 2021-05-31

HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib.

Fan Y, Qin J, Han N, Lu H.

Ann Palliat Med · journal article; case reports · DOI 10.21037/apm-21-213

Bibliografisk träff 2021-04-03

Poziotinib treatment in intractable NSCLC: Epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation disease.

Rosell R, Cardona Zorrilla AF.

Eur J Cancer · comment; research support, non-u.s. gov't; editorial · DOI 10.1016/j.ejca.2021.02.039

Bibliografisk träff 2021-04-02

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.

Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Nichetti F, Manglaviti S, Occhipinti M, Labianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC.

Eur J Cancer · journal article · DOI 10.1016/j.ejca.2021.02.038

Bibliografisk träff 2021-01-05

Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method.

Wang J, Chen F, Jiang H, Xu J, Meng D, Geng P, Dai D, Hu J, Zhou Y, Zhou Q, Wang S.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2020.593518

Bibliografisk träff 2020-11-04

Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells.

Zhang Y, Wu ZX, Yang Y, Wang JQ, Li J, Sun Z, Teng QX, Ashby CR, Yang DH.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers12113249

Bibliografisk träff 2020-10-06

Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness.

Lee H, Kim JW, Lee DS, Min SH.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms21197379

Bibliografisk träff 2020-08-28

Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.

Kim JY, Park K, Im SA, Jung KH, Sohn J, Lee KS, Kim JH, Yang Y, Park YH.

Breast Cancer Res Treat · journal article · DOI 10.1007/s10549-020-05891-0

Bibliografisk träff 2020-08-07

Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib.

Tchekmedyian N, Paxton B, Lebel F, Keossayan L, Heymach JV.

JTO Clin Res Rep · journal article; case reports; case-report · DOI 10.1016/j.jtocrr.2020.100081

Bibliografisk träff 2020-04-01

Poziotinib and bovine serum albumin binding characterization and influence of quercetin, rutin, naringenin and sinapic acid on their binding interaction.

Zargar S, Alamery S, Bakheit AH, Wani TA.

Spectrochim Acta A Mol Biomol Spectrosc · journal article · DOI 10.1016/j.saa.2020.118335

Bibliografisk träff 2020-03-20

Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway.

Lee H, Kim JW, Choi DK, Yu JH, Kim JH, Lee DS, Min SH.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2020.03.046

Bibliografisk träff 2019-09-01

Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib.

Yang J, Yang J, Ban S, Li X, Chen X, Yang J, Qian J.

J Thorac Oncol · letter; research support, non-u.s. gov't; case reports · DOI 10.1016/j.jtho.2019.04.031

Bibliografisk träff 2019-04-03

A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer.

Kim TY, Han HS, Lee KW, Zang DY, Rha SY, Park YI, Kim JS, Lee KH, Park SH, Song EK, Jung SA, Lee N, Kim YH, Cho JY, Bang YJ.

Gastric Cancer · clinical trial, phase ii; comparative study; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10120-019-00958-4

Bibliografisk träff 2018-11-07

A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.

Park YH, Lee KH, Sohn JH, Lee KS, Jung KH, Kim JH, Lee KH, Ahn JS, Kim TY, Kim GM, Park IH, Kim SB, Kim SH, Han HS, Im YH, Ahn JH, Kim JY, Kang J, Im SA.

Int J Cancer · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1002/ijc.31651

Go to research.

Publications in the selection

Assessments of CYP‑inhibition‑based drug-drug interaction between vonoprazan and poziotinib <i>in vitro</i> and <i>in vivo</i>.

Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?

Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC-MS/MS.

Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).

New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.

A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma.

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials.

Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.

Poziotinib-induced cutaneous adverse reactions in the treatment of non-small cell lung cancer: A case report.

Effects of dacomitinib on the pharmacokinetics of poziotinib <i>in vivo</i> and <i>in vitro</i>.

Poziotinib in Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.

Diffuse scaly erythematous plaques in patient taking poziotinib.

Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.

HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib.

Poziotinib treatment in intractable NSCLC: Epidermal growth factor receptor and human epidermal growth factor receptor 2 exon 20 insertion mutation disease.

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.

Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes <i>In Vivo</i> and in an <i>In Vitro</i> Cocktail Method.

Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells.

Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness.

Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.

Prolonged Central Nervous System Response in a Patient With <i>HER2</i> Mutant NSCLC Treated With First-Line Poziotinib.

Poziotinib and bovine serum albumin binding characterization and influence of quercetin, rutin, naringenin and sinapic acid on their binding interaction.

Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway.

Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib.

A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer.

A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.